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Phase I Safety and Immunogenicity Evaluations of an Alphavirus
Replicon HIV-1 Subtype C gag Vaccine in Healthy HIV-1-Uninfected
Adults
M. Wecker,a P. Gilbert,a N. Russell,a* J. Hural,a M. Allen,b M. Pensiero,b J. Chulay,c* Ya-Lin Chiu,a* S. S. Abdool Karim,d D. S. Burke,e*
the HVTN 040/059 Protocol Team, and the NIAID HIV Vaccine Trials Network
Fred Hutchinson Cancer Research Center, Seattle, Washington, USAa; Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USAb;
AlphaVax, Inc., Research Triangle Park, North Carolina, USAc; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Nelson R.
Mandela School of Medicine, Durban, South Africad; and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USAe
On the basis of positive preclinical data, we evaluated the safety and immunogenicity of an alphavirus replicon HIV-1 subtype C
gag vaccine (AVX101), expressing a nonmyristoylated form of Gag, in two double-blind, randomized, placebo-controlled clinical
trials in healthy HIV-1-uninfected adults. Escalating doses of AVX101 or placebo were administered subcutaneously to partici-
pants in the United States and Southern Africa. Because of vaccine stability issues, the first trial was halted prior to completion of
all dose levels and a second trial was implemented. The second trial was also stopped prematurely due to documentation issues
with the contract manufacturer. Safety and immunogenicity were evaluated through assessments of reactogenicity, reports of
adverse events, and assessment of replication-competent and Venezuelan equine encephalitis (VEE) viremia. Immunogenicity
was measured using the following assays: enzyme-linked immunosorbent assay (ELISA), chromium 51 (51Cr)-release cytotoxic T
lymphocyte (CTL), gamma interferon (IFN-) ELISpot, intracellular cytokine staining (ICS), and lymphoproliferation assay
(LPA). Anti-vector antibodies were also measured. AVX101 was well tolerated and exhibited only modest local reactogenicity.
There were 5 serious adverse events reported during the trials; none were considered related to the study vaccine. In contrast to
the preclinical data, immune responses in humans were limited. Only low levels of binding antibodies and T-cell responses were
seen at the highest doses. This trial also highlighted the difficulties in developing a novel vector for HIV.
Despite advances in HIV treatment and prevention, the viruscontinues to spread, especially in sub-Saharan Africa, where
the need for a safe, accessible vaccine for the prevention of HIV
infection is critical.
Venezuelan equine encephalitis (VEE) virus belongs to the
family of alphaviruses—single-stranded, positive-sense RNA vi-
ruses with two open reading frames, one encoding the capsid and
envelope structural proteins and the other encoding the nonstruc-
tural proteins that transcribe and replicate the viral RNA. Al-
though alphaviruses can infect humans, the primary host of the
VEE virus is the horse. Foreign genes (e.g., HIV gag) can be in-
serted in place of the VEE structural protein gene region in a
cDNA plasmid, and an RNA transcript from such a plasmid, when
introduced into cells, will be amplified and express the foreign
genes. This self-amplifying RNA (replicon) will direct the synthe-
sis of very large amounts of the foreign gene product within the
cell, typically reaching levels of 15 to 20% of total cell protein (15).
The replicon RNA can be packaged in vitro into virus-like replicon
particles (VRP) by supplying the structural protein genes of VEE
virus in trans, from helper RNA molecules that are amplified by
the VEE virus nonstructural proteins (Fig. 1). VRP are morpho-
logically identical to live alphavirus particles and retain similar cell
tropisms but are safe, single-cycle, propagation-defective vectors
that are genetically restricted to a single round of infection and
expression due to deletion of the structural protein genes from the
replicon RNA. The use of VRP based on VEE virus as a vaccine
vector is especially attractive because they express heterologous
proteins to high levels, target expression to dendritic cells, and are
capable of inducing both humoral and cellular immune responses
to the vectored gene products (3, 4, 8, 10, 11, 16, 18, 19).
AVX101 is an alphavirus replicon vaccine in which the alpha-
virus structural proteins have been replaced with HIV-1 subtype C
gag. Preclinical immunogenicity studies of AVX101 in mice and
rabbits revealed consistent antibody responses to Gag. In mice
receiving two doses, 3 weeks apart, of 1  105 infectious units (IU)
by subcutaneous (s.c.) footpad injections, the geometric mean
reciprocal antibody titers 1 week after the second injection were
5,747 and 6,451 for two different good manufacturing practice
(GMP) lots of AVX101 (compared to 40 for the controls). In
mice, cellular immune responses were robust and consistently in-
duced Gag-specific cytotoxic T lymphocyte (CTL) responses, as
measured by chromium 51 (51Cr)-release CTL assay and gamma
interferon (IFN-) enzyme-linked immunosorbent spot assay
(ELISpot) assay (2). In a standard 51Cr release assay of splenic
lymphocytes from mice immunized with two doses of 105 IU
AVX101, a Gag-specific CTL response was observed for cells stim-
Received 7 May 2012 Returned for modification 19 June 2012
Accepted 9 August 2012
Published ahead of print 22 August 2012
Address correspondence to M. Wecker, mwecker@fhcrc.org.
* Present address: N. Russell, Bill & Melinda Gates Foundation, Seattle, Washington,
USA; J. Chulay, Applied Genetic Technologies Corporation, Alachua, Florida, USA;
Ya-Lin Chiu, Weill Cornell Medical College, New York, New York, USA; D. S. Burke,
Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Supplemental material for this article may be found at http://cvi.asm.org/.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/CVI.00258-12
October 2012 Volume 19 Number 10 Clinical and Vaccine Immunology p. 1651–1660 cvi.asm.org 1651
 on F




















ulated with either a recombinant vaccinia virus expressing an HIV
subtype C gag gene or with an H-2Kd-restricted Gag peptide, rep-
resenting the immunodominant CTL epitope. A Gag-specific
CD8 T-cell response was also observed using an IFN- ELISpot
assay with a mean of 219 spot-forming cells (SFC)/106 cells (com-
pared to 0 for the control) (7).
Based on these positive preclinical results, a clinical trial pro-
gram was initiated. The results reported here include data from
two separate clinical trial protocols (HVTN 040 and HVTN 059).
The primary objective of these double-blind, randomized clinical
trials was to evaluate the safety and tolerability of escalating doses
of AVX101. The secondary objective was evaluation of immuno-
genicity as measured by IFN- ELISpot, 51Cr-release CTL, lym-
phoproliferation, and intracellular cytokine staining (ICS) assays,
binding antibody by enzyme-linked immunosorbent assay
(ELISA), and anti-VEE virus antibodies using a VRP neutraliza-
tion assay.
HVTN 040 was designed to evaluate the safety of four escalat-
ing doses (1  104, 1  105, 1  106, and 1  107 IU) of AVX101
in healthy, HIV-1-uninfected adults. During the study, 9-month
stability testing showed that the two higher vaccine doses (1  106
and 1  107 IU) stored at 20°C were below the release specifi-
cation due to loss of titer when stored at 20°C but not when
stored at 80°C. The storage conditions were changed from
20°C to 80°C for the two lower doses (104 and 105 IU) of the
existing clinical trial material to minimize potential further de-
creases in potency at these dose levels, and the original protocol,
HVTN 040, was modified to include only the two lower doses, 1 
104 and 1  105 IU.
Improvements in the methods for manufacturing AVX101 en-
abled production of larger quantities and higher concentrations of
the vaccine, allowing evaluation of dosage levels up to 1  108 IU
per injection. Therefore, HVTN 059 was designed to obtain addi-
tional safety and immunogenicity data by evaluating higher doses
of AVX101 in healthy HIV-1-uninfected adults. This second pro-
tocol repeated testing of the 1  105 IU dose and included addi-
tional dose levels of 1  106, 1  107 and 1  108 IU. HVTN 040
and HVTN 059 had identical objectives and outcomes and were
conducted at the same clinical sites. In November 2005, potential
issues with the contract manufacturer’s documentation and envi-
ronmental monitoring program were identified, and further in-
jections were terminated, reducing the number of persons en-
rolled at the highest dose level. This report includes results from
both the 040 and 059 clinical trials.
MATERIALS AND METHODS
Participants. A total of 144 participants were to be enrolled, half in Africa
(South Africa and Botswana) and half at sites in the United States, and
randomized to receive either AVX101 or placebo in a 5:1 ratio. Partici-
pants were eligible for enrollment if they were between the ages of 18 and
60 for HVTN 040 or 18 and 50 years for HVTN 059, were HIV-1 unin-
fected, were in good general health, demonstrated an understanding of the
purpose of the study, and provided informed consent. Female partici-
pants were required to agree to use birth control, not to breastfeed, and
not to become pregnant during the course of the study.
Interventions. The AVX101 vaccine contains an RNA replicon that
was constructed by replacing the structural genes of an attenuated strain
of VEE virus with the gag gene from a South African isolate (DU422) of
subtype C HIV-1. The gag gene cDNA was modified by site-specific mu-
tagenesis to remove the amino-terminal myristoylation site of Gag in
order to prevent the formation of Gag-derived virus-like particles. The
recombinant replicon was packaged into VRP by transfecting Vero cells
with replicon RNA and two helper RNAs that express the structural pro-
teins of the attenuated strain of VEE virus.
AVX101 was supplied by AlphaVax, Inc., Research Triangle Park, NC,
as a sterile, clear solution in single-dose vials formulated at 5 different
concentrations (1  104, 1  105, 1  106, 1  107, and 1  108 IU per 0.5
ml) and containing phosphate-buffered saline, pH 7.2, human serum al-
bumin (HSA), sodium gluconate, and sucrose as a cryopreservative. The
matching placebo (phosphate-buffered saline, pH 7.2, HSA, sodium glu-
conate, and sucrose) was also supplied by AlphaVax, Inc., as a sterile, clear
solution in single-dose vials. Both AVX101 and placebo were manufac-
tured at a GMP contract manufacturing facility. The same placebo was
used in both trials, and results for all placebo recipients in the two trials
were combined for data analysis.
All injections were 0.5 ml, administered subcutaneously in the upper
arm after preparation of the site with alcohol. Participants and clinic staff
were blinded as to the study product received. Only the clinic pharmacist
had access to the randomization scheme, to allow for product prepara-
tion.
Participants received escalating doses of AVX101. For each dose level,
participants were enrolled at sites in the United States, and safety data
from the day 14 visit were evaluated for all participants at each dose level
before proceeding with enrollment of participants at the same dose level at
sites in Africa and at the next dose level at sites in the United States. The
trial schemas are combined in Table 1.
Safety. Participants received injections of study vaccine or placebo on
days 0, 28, and 84. Participants returned to the clinic for follow-up visits 2
weeks after each injection and again at months 6, 9, and 12 after the first
injection. Reactogenicity assessments were performed for all participants
before and after each injection, beginning 25 to 45 min postinjection and
continuing daily for 7 days. Participants were asked to record their body
temperature at the same time each day for 7 days, and clinical assessments
were made during telephone or clinic visits on days 1, 2, 3, and 7 postvac-
cination. Assessments performed included systemic reactogenicity (body
temperature, malaise and/or fatigue, myalgia, headache, chills, arthralgia,
nausea, vomiting) and local reactogenicity (injection site pain, tender-
ness, erythema or induration, and axillary lymph node tenderness or en-
largement). In addition, participants were queried about adverse experi-
ences at each visit or telephone contact.
Any participant who reported a fever greater than 38°C, or other mod-
erate symptoms consistent with a viral illness (e.g., headache or malaise)
during the 7 days following vaccination, or neurological symptoms (e.g.,
nuchal rigidity, ataxia, convulsions, coma, paralysis) within the window
FIG 1 Virus-like replicon particle vaccine and packaging system.
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of the 2-week postvaccination visit, provided a serum sample to confirm
the absence of replication-competent VEE viremia.
Immunogenicity. The assays for 51Cr-release, ELISpot, and ELISA
were performed at the South African Immunology Laboratory–National
Institute for Communicable Diseases (Johannesburg, South Africa) on
specimens from Southern African participants. For the U.S. participant
specimens these assays were performed at Duke University Medical Cen-
ter (Durham, NC). All assays were conducted in a blinded manner.
Binding antibodies by ELISA. Binding antibodies to commercially
available Gag protein (p55 Gag; Quality Biologicals) were assessed by
ELISA using single serum dilutions (1/50 or 1/100) on samples taken at
baseline, 2 weeks after the second and third vaccinations and at the final
visit. Samples that were positive in the initial ELISA were tested by end-
point titration ELISA using six 2- to 7-fold serial dilutions of serum be-
ginning at a 1/50 or 1/100 dilution. The magnitude of responses is re-
ported as the difference in optical density (OD) in antigen-containing and
non-antigen-containing wells at the 1:50 dilution.
51Cr-release CTL assay. A standard 51Cr-release CTL assay was per-
formed on fresh peripheral blood mononuclear cells (PBMC) at baseline
and 2 weeks after the second and third vaccinations, using a 50:1 effector-
to-target cell (E:T) ratio. Prevaccination samples were utilized to generate
Epstein-Barr virus (EBV)-transformed B-lymphocyte cell lines (BLCL)
from each trial participant. BLCL were infected with a recombinant vac-
cinia virus expressing HIV Gag, loaded with 51Cr, and used as targets for
PBMC effectors isolated from the participant’s autologous fresh whole
blood. Responses are reported as percent HIV-specific 51Cr release.
IFN- ELISpot assay. Bulk T-cell responses were assessed by IFN-
ELISpot using cryopreserved PBMC at 200,000 cells per well, stimulated
overnight with Gag peptide pools. Protocol-specific peptide pools in-
cluded HIV-1 15-mer peptides overlapping by 11 amino acids (80 to 95%
purity). Peptide pools covered the DU422 isolate Gag protein sequence
with a total of 121 peptides. Peptides were provided at 80% purity from
the NIH AIDS Reagents and Reference Repository Program. For these
protocols, we used 3 peptide pools as follows: DU422-gag pool 1, Gag 1
peptides 1 to 40; DU422-gag pool 2, Gag 2 peptides 41 to 80; and DU422-
gag pool 3, Gag 3 peptides 81 to 121.
ELISpot assays were performed at baseline and 2 weeks after the sec-
ond and third vaccinations. Responses are reported as the number of
spot-forming cells (SFC) per 106 PBMC recognizing any of the three Gag
peptide pools evaluated.
Intracellular cytokine staining (ICS) assay. For participants in
HVTN 059, flow cytometry was used to examine HIV-specific CD4 and
CD8 T-cell responses using ICS, following stimulation with Gag pep-
tides that span the protein sequence encoded by the vaccine construct. ICS
assays were performed at the Fred Hutchinson Cancer Research Center
Laboratories. Assays were performed at baseline and 2 weeks after the
second and third vaccinations. Responses are reported as percentages of
CD4 or CD8 T cells recognizing any peptide pool.
LPA. For participants in HVTN 040, a lymphocyte proliferation
assay (LPA) in response to purified Gag protein and/or Gag peptides
was performed on cryopreserved PBMC collected at baseline, 2 weeks
after the second and third vaccinations, and at the final visit. The LPA
was conducted at the Fred Hutchinson Cancer Research Center Labo-
ratories.
Antibodies to VEE virus. To evaluate the development of anti-vector
immune responses, neutralizing antibodies to VEE virus were measured
in serum obtained at baseline, 2 weeks after the second and third vaccina-
tions, and at the final visit, using a green fluorescent protein (GFP) VRP
neutralization assay performed at AlphaVax, Inc. Samples were screened
at a 1:10 dilution, and those with a positive response (50% neutraliza-
tion in the number of cells expressing GFP) were retested using serial
2-fold dilutions. The magnitude of responses in responders is reported as
the sample dilution at which GFP levels were reduced by 50% compared
to GFP levels in virus control wells after subtraction of background GFP in
cell control wells.
Sample size. The sample size at each vaccine dose level was selected
such that the stopping rule for not escalating the dose (2 or more vaccine-
related grade IV adverse experiences) would be met with high probability
if the true toxicity rate was above 15 to 20% and such that dose escalation
would occur with high probability if the true toxicity rate was less than
5%. The studies planned for 20 participants to receive each of the 1  104,
1  106, 1  107, and 1  108 IU vaccine dose levels and for 40 participants
to receive the 1  105 IU vaccine dose level, evenly divided among the U.S.
and Southern African participants for each dose level. Based on the
planned 20 vaccine recipients evaluable for the toxicity endpoint, if the
true rate of toxicity is less than 5%, then there is at least a 0.74 probability
that dose escalation would occur. If the true rate of toxicity is 10%, 20%,
or 30%, respectively, then there are probabilities of 0.61, 0.93, and 0.99,
respectively, to stop the dose escalation. Sample size calculations were
not performed for the immunogenicity endpoints because they were
secondary.
Randomization. For both HVTN 040 and HVTN 059, the random-
ization sequence was obtained by computer-generated random numbers
and provided to each site using standard statistical and data management
center (SDMC) procedures in place at the Statistical Center for HIV/AIDS
Research and Prevention (SCHARP). For each region separately (United
States and Southern Africa), the lists allocated participants to each dose
group and to active or placebo within each dose group, using permuted
blocks of 6 treatments (5 active, 1 placebo). The randomization code was
kept at each institution by the pharmacist of record with primary respon-
sibility for drug dispensing. Syringes containing vaccine or placebo were
provided to the investigators and clinic staff in a blinded fashion by the
pharmacist at the clinical study site.
Statistical methods. Data were analyzed according to a slightly mod-
ified intention-to-treat approach, wherein all subjects receiving the first
vaccination were included in the analysis, and analyzed based on initial
randomization assignment regardless of the number of injections re-
ceived. Immunogenicity of the vaccine was measured by the rate of posi-
tive response (for each group and time point) for each assay type described
above. Ninety-five percent confidence intervals for the positive response
rates were computed with the Wilson method (1). Fisher’s exact tests were
used to compare positive response rates between study groups. For ELISA,
ICS, and LPA data, immunogenicity of the vaccine was also measured by
TABLE 1 Study schemaa
Groupb Dose (IU)
No. of
participantsc Injection schedule in mo (days)
US SA 0 1 (28) 3 (84)
1 1  104 10 10 Vaccine Vaccine Vaccine
2 2 Placebo Placebo Placebo
2 1  105 20 20 Vaccine Vaccine Vaccine
4 4 Placebo Placebo Placebo
3 1  106 10 10 Vaccine Vaccine Vaccine
2 2 Placebo Placebo Placebo
4 1  107 10 10 Vaccine Vaccine Vaccine
2 2 Placebo Placebo Placebo
5 1  108 10 10 Vaccine Vaccine Vaccine
2 2 Placebo Placebo Placebo
a IU, infectious units; US, United States; SA, Southern Africa (South Africa and
Botswana).
b Group 1 and half of group 2 were enrolled in HVTN 040; the remainder of group 2, as
well as groups 3 to 5, was enrolled in HVTN 059.
c There were 72 participants (60 given the vaccine and 12 given the placebo) for each
geographical group, for a total of 144 participants (120 given the vaccine and 24 given
the placebo).
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the median magnitude of response among those with a positive response.
These magnitudes were compared between study groups with the Mann-
Whitney test. To improve statistical power for detecting vaccine-induced
immune responses and simplifying the presentation, the placebo
groups for the HVTN 040 and 059 trials were combined for assessing
vaccine immunogenicity. This introduces minimal risk of bias because
the placebos were identical for the two trials and the same lab per-
formed the assays. Ten vaccine groups were analyzed separately: the
1  104 and 1  105 IU doses for HVTN 040 in the United States and
in Southern Africa, the 1  105, 1  106, 1  107, and 1  108 IU doses
for HVTN 059 in the United States, and the 1  105 and 1  106 IU
doses for HVTN 059 in Southern Africa. Immunogenicity was evalu-
ated on days 0, 42, 98, 168, and 364 of visits, with day 98 the primary
time point. All statistical tests were two-sided and were deemed statis-
tically significant if P was 0.05.
ELISA. Response to Gag was considered positive if the difference in
duplicate antigen-containing and non-antigen-containing wells had an
OD of 0.2. The positivity criterion for the ELISA was established
through validation studies comparing sensitivity and specificity of the
assay using samples from HIV-infected donors, recipients of HIV vac-
cines, and normal healthy donors. The criterion of 0.2 OD units was
selected to ensure a low false-positive rate while maintaining a reasonable
level of sensitivity.
51Cr-release CTL assay. The CD8 CTL response was considered pos-
itive if all of the following three conditions held: (i) specific lysis for the
HIV-1 antigen-expressing targets relative to the control was 10%; (i)
this specific lysis decreased by at least 50% after removal of CD8 cells;
and (iii) this specific lysis was 5% after removal of CD4 cells. Response
rates were computed for HIV-1 antigen-expressing targets.
IFN- ELISpot assay. To determine a positive response to a specific
peptide pool, the bootstrap test described by Moodie et al. (12) was used to
test the null hypothesis—that the mean result for the experimental wells
was equal to twice the mean for the negative-control wells, versus the
alternative that the experimental mean was greater— based on log10-
transformed data. This method adjusts for the multiple peptide pools by
calculating step-down, maxT-adjusted P values. Peptide pools with ad-
justed one-sided P values of 0.05 were considered positive. In addition
to a significant P value, the mean background-subtracted response for the
peptide pool must have been 10 SFC/200,000 PBMC for the peptide
pool to be considered positive. This criterion ensures demonstration of a
minimum level of biological activity. If the response to any of the three
peptide pools was positive, then the overall response was considered pos-
itive.
Intracellular cytokine staining (ICS) assay. To assess positivity, two-
by-two contingency tables were constructed comparing the HIV-1 pep-
tide-stimulated and negative-control data for each peptide pool and the
two T-cell subsets (CD4 or CD8) expressing IFN- or interleukin 2 (IL-2).
Cytokine subsets with negative staining for both IFN- and IL-2 were not
of interest and therefore were not included in the analysis. In these con-
tingency tables, the four entries are the number of cells positive and the
number of cells negative for IL-2 or IFN- for both the stimulated and the
negative-control data. A one-sided Fisher exact test was applied to each
table, to test whether the number of cytokine-producing cells for the stim-
ulated data was equal to that for the negative-control data. Since multiple
individual tests (for each peptide pool and for each T-cell subset) were
conducted simultaneously, a multiplicity adjustment was made using the
discrete Bonferroni method (17). The adjusted P values were used to
determine positivity, with values of 0.00001 indicating a positive re-
sponse. If at least one peptide pool for a specific gene was positive, then the
overall response to the gene was considered positive. If any peptide pool
was positive for a T-cell subset, then the overall response for that T-cell
subset was considered positive.
Lymphocyte proliferation assay (LPA). For each peptide pool, a pos-
itive lymphocyte proliferation response was defined as a stimulation index
greater than 3. If the response to any peptide pool was positive, then the
overall response was considered positive.
RESULTS
Enrollment and demographics. For HVTN 040, the first partici-
pant was enrolled in July 2003, the last participant was enrolled in
May 2004, and follow-up was complete in July 2005. For HVTN
059, the first participant was enrolled in October 2004, the last
participant was enrolled in October 2005, and follow-up was com-
pleted in September 2006. As noted above, in November 2005 a
decision was made to halt all further injections of study product
due to product manufacturing issues.
The numbers of participants who received each vaccine injec-
tion are shown in Table 2. Of the 132 enrolled participants, 109
(83%) received all 3 planned injections. Of those who did not
complete the study, only 3 (2%) discontinued due to adverse
events (discussed in detail below). Enrollment of the third dose
level in Southern Africa was under way when the decision to halt
further injections was made, and thus only 2 of 10 participants in
this group received a second dose of vaccine and none received a
third dose.
A summary of the demographics is provided in Table 3. The
vaccine and control groups were well balanced with regard to de-
mographics. The median age was 29.5 years (range, 20 to 55 years).
Safety. A summary of reactogenicity symptoms is provided in
Fig. 2. Overall, 64 (48.5%) subjects reported mild local reactions,
with no obvious relationship to dose level or number of injections
received. Only 3 participants (2.3%) reported moderate pain or
tenderness at the injection site. Systemic reactogenicity symptoms
were reported by 78 (59.1%) subjects, most of which were mild in
intensity, with the patterns of response similar between the vac-
cine and control groups.
There were 5 serious adverse events reported during the trials,
none of which were considered related to the study vaccine. These
reports included hospitalization following a car accident 1 month




No. of participants who received
injection no. [mo (day)]
1 [0] 2 [1 (28)] 3 [3 (84)]
US SA US SA US SA
1 1  104 Vaccine 10 10 10 9 9 9
Placebo 2 2 2 2 2 2
2 1  105 Vaccine 20 20 18 20 18 19
Placebo 4 4 4 4 4 4
3 1  106 Vaccine 10 10 9 10 9 8
Placebo 2 2 2 2 2 1
4 1  107 Vaccine 10 10 10 2 10 0
Placebo 2 2 2 0 2 0
5 1  108 Vaccine 10 0 10 0 9 0
Placebo 2 0 1 0 1 0
Total Vaccine 60 50 57 41 55 36
Placebo 12 10 11 8 11 7
a IU, infectious units; US, United States; SA, Southern Africa (South Africa and
Botswana).
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after receiving the 3rd injection of 1  104 IU of AVX101, hospi-
talization for epigastric discomfort (attributed to pregnancy)
which began 4 months after the 3rd injection of 1  106 IU of
AVX101, hospitalization for suicidal ideation which began 4
months after the 3rd injection of 1  107 IU of AVX101, hospital-
ization for elevated liver function tests and hyperglycemia 6
months after the 3rd injection of the control, and severe hyperten-
sion noted 2 weeks after the first injection of 1  106 IU of
AVX101. The participant who became pregnant delivered a full-
term healthy baby. After delivery, the participant was diagnosed as
HIV infected, but her baby remained uninfected.
Additional events reported to the sponsor on an expedited ba-
sis, but not considered serious, were infectious hepatitis A or E,
severe fatigue, and severe headache, each in one participant.
TABLE 3 Demographics and vaccination frequencies
Parametera
Result for vaccine and dose (IU)






















Male 4 (50%) 12 (60%) 9 (45%) 25 (52%) 9 (64%) 10 (50%) 13 (65%) 10 (50%) 5 (50%) 47 (56%)
Female 4 (50%) 8 (40%) 11 (55%) 23 (48%) 5 (36%) 10 (50%) 7 (35%) 10 (50%) 5 (50%) 37 (44%)
Race
White non-Hispanic 4 (50%) 7 (35%) 5 (25%) 16 (33%) 3 (21%) 10 (50%) 5 (25%) 9 (45%) 4 (40%) 31 (37%)
Black/African American
non-Hispanic
3 (38%) 12 (60%) 14 (70%) 29 (60%) 8 (57%) 10 (50%) 14 (70%) 11 (55%) 3 (30%) 46 (55%)
Hispanic 1 (13%) 1 (5%) 0 (0%) 2 (4%) 2 (14%) 0 (0%) 0 (0%) 0 (0%) 3 (30%) 5 (6%)
Native Hawaiian/Pacific Islander
or multiracialb
0 (0%) 0 (0%) 1 (5%) 1 (2%) 1 (7%) 0 (0%) 1 (5%) 0 (0%) 0 (0%) 2 (2%)
Age (yr)
18–20 1 (13%) 0 (0%) 1 (5%) 2 (4%) 1 (7%) 2 (10%) 0 (0%) 2 (10%) 0 (0%) 5 (6%)
21–30 2 (25%) 9 (45%) 13 (65%) 24 (50%) 9 (64%) 10 (50%) 10 (50%) 8 (40%) 4 (40%) 41 (49%)
31–40 1 (13%) 3 (15%) 2 (10%) 6 (13%) 3 (21%) 3 (15%) 4 (20%) 5 (25%) 2 (20%) 17 (20%)
41–50 2 (25%) 7 (35%) 4 (20%) 13 (27%) 1 (7%) 5 (25%) 6 (30%) 5 (25%) 4 (40%) 21 (25%)
Over 50 2 (25%) 1 (5%) 0 (0%) 3 (6%)
Median 39.5 32.0 27.0 29.5 25.5 26.5 30.5 29.5 32.0 28.5
Range 20–55 21–54 20–48 20–55 20–48 20–48 21–50 18–45 24–46 18–50
Vaccination frequencies
Day 0 8 (100%) 20 (100%) 20 (100%) 48 (100%) 14 (100%) 20 (100%) 20 (100%) 20 (100%) 10 (100%) 84 (100%)
Day 28 8 (100%) 19 (95%) 18 (90%) 45 (94%) 11 (79%) 20 (100%) 19 (95%) 12 (60%) 10 (100%) 72 (86%)
Day 84 8 (100%) 18 (90%) 17 (85%) 43 (90%) 10 (71%) 20 (100%) 17 (85%) 10 (50%) 9 (90%) 66 (79%)
a Results are no. (%) unless otherwise noted.
b Data represent Native Hawaiian/Pacific Islander subjects for HVTN 040 and multiracial subjects for HVTN 059.
FIG 2 Maximum local (A) and systemic (B) reactogenicity following each dose (1, 2, or 3) at each dose level.
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In addition to the participant with a severe headache men-
tioned above, there were 28 other participants who met the pro-
tocol requirements to have blood drawn and tested for VEE
viremia. All cultures were negative.
Three participants discontinued their vaccinations due to ad-
verse events. One was a 55-year-old white male with a history of
Bell’s palsy who had a recurrence of Bell’s palsy 2 weeks after the
first injection of AVX101 (1  105 IU). He was treated with Val-
trex (valacyclovir) and prednisone. This event was considered
possibly related to the vaccine. The second was a 30-year-old black
male with neutropenia 2 weeks after receiving the first injection of
AVX101 (1  105 IU). He had met the study entrance criteria at
the time of enrollment; however, his white blood cell count and
neutrophil count were low. His absolute neutrophil count fluctu-
ated, increasing before the second scheduled injection at month 1
but dropping again after that injection. It was decided to discon-
tinue vaccinations prior to the third scheduled injection, and the
event was considered probably not related to the vaccine. The
third was a 32-year-old white female who requested not to receive
the third injection of AVX101 (1  108 IU) due to fatigue. Ap-
proximately 1 week following the second injection she developed
a streptococcal infection and subsequently received an intramus-
cular injection of Rocephin (ceftriaxone) which resulted in a se-
vere rash within 24 h. After 10 days the rash resolved, but the
fatigue continued. This event was considered probably not related
to the vaccine.
There were no deaths reported during the trials.
Immunogenicity. The numbers of randomized participants
included in the immunogenicity analyses are described in Table S1
in the supplemental material. For the ELISA, 51Cr-release CTL,
LPA, and ELISpot assays, evaluable immunogenicity data at day
98 (the primary immunogenicity time point) were available for 70
to 100% of participants in the various dose groups. For ICS the
rate was lower (40 to 100% across the dose levels). The most com-
mon reasons for missing data were a missed visit or an invalid
blood draw (93.7%).
A dose-dependent antibody response to AVX101 was noted
(Fig. 3 and Table 4). There were no positive Gag ELISA responses
in subjects who received placebo or vaccine at the 1  104 IU dose,
and only one vaccine recipient had a positive response at the 1 
105 IU dose. For the three highest dose levels there was a progres-
sive increase in the proportion of subjects with a positive response,
and the response rates in the 1  107 IU (80%) and 1  108 IU
(100%) dose groups were significantly greater than those in the
placebo group (P  0.0003 and P  0.0001) and the 1  106 IU
dose group (P  0.017 and P  0.0001). At the highest dose, the
average ELISA magnitude (background-subtracted OD) was 0.55.
The cellular immune response as measured by 51Cr-release, IFN-
ELISpot, and ICS assays was quite modest and often did not dem-
onstrate a clear dose response. Data from the 51Cr-release assay
showed three subjects with a positive CD8 CTL response at day
FIG 3 ELISA responses 2 weeks after 3rd vaccination (day 98). A solid dot represents a positive response, and an open dot is for a negative response. Numbers
at the top show the number of responders/number of assay results and the percentage with a positive result. For each box plot, 25% of the data points lie below
the box and 25% lie above the box, and the horizontal line inside the box is the median. The vertical lines (whiskers) above and below the box extend to the most
extreme data point, which is no more than 1.5 times the height of the box.
TABLE 4 ELISA response rates by regiona
Dose
No. with positive ELISA/total no. tested
United States Southern Africa
2 wk post 2nd
vac (day 42)
2 wk post 3rd
vac (day 98)
2 wk post 2nd
vac (day 42)
2 wk post 3rd
vac (day 98)
105 0/10 0/10 0/10 1/10
106 2/10 3/10 0/8 0/6
107 3/10 8/10 NA NA
108 8/10 10/10 NA NA
a vac, vaccination; NA, not applicable.
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98, all from Southern Africa, at vaccine doses of 1  105 or 1  106
IU, and a positive CD4 CTL response in one subject in the
United States at a vaccine dose of 1  106 IU (Fig. 4). Only one
subject had a positive IFN- ELISpot response, a U.S. vaccine
recipient receiving 1  107 IU (Fig. 5). ICS was performed only for
HVTN 059 participants in the United States. Only one subject had
a positive CD8 response, at a dose of 1  106 IU. In contrast, 2 of
8, 2 of 9, 5 of 10, and 4 of 10 vaccine recipients at doses of 1  105,
1  106, 1  107, and 1  108 IU, respectively, had a positive CD4
response at day 98 (Fig. 6). Although a response could be consid-
ered positive if cells expressed only IFN-, only IL-2, or both
IFN- and IL-2, all positive responses detected both IFN- and
IL-2. The ICS data support higher response rates for the two high-
est dose groups compared to the control group (P  0.0026, P 
0.13).
LPA was performed only for participants in HVTN 040, in
which only 1  104 and 1  105 IU doses were administered. Two
subjects had positive responses to the Gag-1 pool at day 98, one
each in the 1  104 and 1  105 IU vaccine dose groups. Three
subjects had day 98 responses to the Gag-2 pool, 2 in the 1  104
IU group and 1 in the 1  105 IU group. Twelve subjects had day
98 responses to the p24 pool (2 in the placebo group and 5 in each
of the 1  104 and 1  105 IU groups), and 14 subjects had a day
98 response to the p55 pool (2 in the placebo group, 7 in the 1 
104 IU group and 5 in the 1  105 IU group). The LPA response
rates were similar in the vaccine groups and the control group
(P  0.5 for each peptide pool).
Anti-VEE virus antibody. At baseline, only one subject (a U.S.
participant in the 1  105 IU dose group in HVTN 040) had a
positive anti-VEE virus antibody titer (1:10). At day 98, a positive
anti-VEE titer was detected in 0/18, 0/19, 3/38, 6/18, 10/10, and
10/10 subjects in the placebo, 1  104, 1  105, 1  106, 1  107,
and 1  108 IU dose groups, respectively. The geometric mean
titers (GMT) for positive responses were 10, 160, 1,194, and 4,159
in the 1  105, 1  106, 1  107, and 1  108 IU dose groups,
respectively.
DISCUSSION
These phase I trials of a recombinant VRP vaccine expressing a
subtype C gag gene, modified to express nonmyristoylated Gag,
demonstrated that the AVX101 vaccine was well tolerated in
healthy adults at doses of up to 1  108 IU and that despite prom-
ising preclinical immunogenicity data, there were only modest
immune responses among these trial participants. These trials also
highlighted the difficulties in developing a novel vector for HIV.
The trials were conducted sequentially over 3 years (2004 to 2006).
Each trial was terminated early: one trial due to loss of vaccine titer
during storage and the other due to potential issues with the con-
tract manufacturer.
The vaccine was well tolerated and exhibited only modest local
reactogenicity, similar to the modest reactogenicity seen in a phase
I clinical trial of a VRP vaccine expressing cytomegalovirus
(CMV) antigens (5). Few severe adverse events were reported dur-
ing the studies. Subjects were enrolled in the two studies, in the
United States and Southern Africa, successfully, and safety assess-
ments in the two populations were similar.
The ELISA data revealed consistent dose-dependent antibody
responses in participants who received the higher doses of vaccine
(1  106 to 1  108 IU), with 3/10, 8/10 and 10/10 U.S. partici-
pants responding; however, the magnitude was much lower than
FIG 4 51Cr release. The left panel shows CD4 responses 2 weeks after 3rd vaccination (day 98), presented as the percentage of specific lysis after CD8 depletion.
The right panel shows the CD8 responses at the same time point, presented as the percentage of specific lysis after CD4 depletion. A solid dot represents a positive
response, and an open dot represents a negative response. Numbers at the top show the number of responders/number of assay results. For each box plot, 25%
of the data points lie below the box and 25% lie above the box, and the and the horizontal line inside the box is the median. The vertical lines (whiskers) above
and below the box extend to the most extreme data point, which is no more than 1.5 times the height of the box.
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was seen in preclinical studies. Using an assay in which the end-
point titer was the last dilution eliciting an OD of 0.20, the
ELISA GMT ranged from 4,200 to 6,450 after two injections of 1 
105 IU of AVX101 in four studies in mice and was 508, 1,280, and
3,620 after three injections of AVX101 in rabbits at doses of 1 
106, 1  107, and 2  108 IU, respectively (2). In contrast, using an
assay in which the OD at a 1:50 serum dilution was determined, the
ELISA magnitudes at a dose of 1  108 IU in the clinical trial were
only slightly above the positivity cutoff-adjusted OD of 0.2. In ad-
dition, because the two higher doses (1  107 and 1  108 IU) were
not studied in Southern African participants, any conclusions about
the anti-Gag antibody response are limited to U.S. participants.
Similarly, despite promising results in preclinical studies,
AVX101 was poorly immunogenic in stimulating Gag-specific
cellular immune responses in people. Preclinical immunogenicity
studies of AVX101 in mice demonstrated robust cellular re-
sponses. In mice given two injections of 1  105 IU of AVX101 by
subcutaneous footpad injection, positive ELISpot responses were
detected in 100% of mice, with responses ranging from 75 to 420
SFC per 105 splenocytes, and 51Cr-release CTL assays showed
30% specific lysis at a 50:1 E:T ratio using splenocytes stimu-
lated with Gag peptides and 30% specific lysis at a 6:1 E:T ratio
using splenocytes stimulated with a vaccine-Gag virus (2). Addi-
tionally, a prototype VRP vaccine expressing simian immunode-
ficiency virus (SIV) gag and env genes was associated with high
levels of immunogenicity in nonhuman primates (NHP) (8). In
that trial, rhesus macaques received VRP-expressing proteins en-
coded in the SIVsm H-4i molecular clone. Four inoculations were
administered over a period of 21 weeks: two subcutaneous injec-
tions both at 1  105 IU and two intravenous (i.v.) injections at
1  107 and 5  108 IU. Humoral and cellular immune responses
were measured, and animals were challenged with SIVsm E660
given i.v. Antibody responses to Env were not detected following
the two s.c. injections, but binding antibodies were detected after
the first i.v. inoculation (the GMT measured 3 weeks following the
last vaccination was 17,947). Two of the four vaccinated monkeys
showed strong cellular immune responses to both SIV proteins,
one had a low-level response to either Gag or Env, and the fourth
vaccinated monkey had no detectable cellular response. Four weeks
after immunization, animals were challenged with SIVsm E660 ad-
ministered i.v. All animals were infected; however, two of the four
control animals showed signs of illness by 4 weeks postchallenge and
were eventually sacrificed. All four of the vaccinated animals were
protected from disease progression with a reduction in viral load of
200-fold compared to controls, and there was an inverse relationship
between viral load and humoral and cellular immune response.
In contrast to these positive data from a different VRP vaccine
in nonhuman primates, and the encouraging preclinical data with
AVX101, the data from this clinical trial demonstrated a dose-
dependent anti-Gag antibody response but only a marginal T-cell
response to Gag in humans. Only low levels of binding antibodies
to p55 were achieved at the highest doses (1  107 and 1  108 IU),
notwithstanding the expectation that infection of dendritic cells
by the VRP vaccine would result in a strong immunogenic re-
sponse. T-cell responses as detected by a 7-day 51Cr release CTL
assay were seen in only a few participants and only at the 1  105
and 1  106 IU doses in participants from Southern Africa, and as
measured by ICS assay, CD4 T-cell responses appeared more
frequent than CD8 T-cell responses. By ELISpot assay only one
participant, who received the 1  107 IU dose, had detectable
T-cell responses.
The reasons for the differences between the preclinical and
FIG 5 ELISpot 2 weeks after 3rd vaccination (day 98). Data were obtained only for U.S. participants in study HVTN 059. A solid dot represents a positive
response, and an open dot represents a negative response. Numbers at the top show the number of responders/number of assay results and the percentage with
a positive result. For each box plot, 25% of the data points lie below the box and 25% lie above the box, and the horizontal line inside the box is the median. The
vertical lines (whiskers) above and below the box extend to the most extreme data point, which is no more than 1.5 times the height of the box.
Wecker et al.
1658 cvi.asm.org Clinical and Vaccine Immunology
 on F




















human phase I data are unclear. Preexisting anti-vector immunity
is not the reason, since anti-VEE virus antibodies were present at
enrollment in only one subject. SIV Gag has been shown in several
studies to be more immunogenic than HIV-1 Gag. In addition, the
gag gene cDNA in AVX101 was modified by site-specific mutagen-
esis to remove the amino-terminal myristoylation site in order to
prevent the formation of Gag-derived virus-like particles (VLP)
during production in the Vero packaging cells (6, 9, 14, 20). It was
unclear at the time of the project’s initiation whether the down-
stream purification process would be sufficient to remove the
large majority of contaminating VLP from the VRP vaccine har-
vest. Thus, the modification was employed to simplify the purifi-
cation and characterization of the AVX101 vaccine particle com-
ponents. Based in part on the results of the current clinical trial, an
HIV Gag VRP vaccine has been designed using a gag gene with a
normal myristoylation site. The immunogenicities of VRP vac-
cines expressing nonmyristoylated (myr) Gag (i.e., AVX101)
and myristoylated (myr) Gag were compared in nonhuman pri-
mates (Chinese rhesus macaques) injected at weeks 0, 4, and 24.
Gag-specific T-cell responses as measured by IFN- ELISpot were
positive in 5 of 5 Gag (myr) VRP-vaccinated animals by 4 weeks
after the first dose and remained positive at all later time points. In
contrast, only 4 of 5 AVX101-vaccinated animals had an inconsis-
tent positive response, at only one or two time points after the
second dose. Mean responses were 4- to 5-fold higher in Gag
(myr) VRP-vaccinated animals than in AVX101-vaccinated an-
imals after the 2nd (514 versus 126 SFC/106 PBMC) and 3rd (514
versus 126 SFC/106 PBMC) injections (Olmsted et al., unpub-
lished data). Irrespective of the vaccine received, all animals
mounted anti-Gag antibody responses after two doses of vaccine
and in contrast to the vaccine-specific differences in T-cell re-
sponses, the Gag-specific ELISA titers induced by either vaccine
were of similar magnitude. The results from this comparative im-
munogenicity study are encouraging and may warrant clinical
evaluation of the Gag (myr) VRP vaccine to determine in human
subjects whether a VRP vaccine expressing Gag (myr) would
elicit more frequent and higher-magnitude Gag-specific T-cell re-
sponses than did AVX101.
This clinical study with AVX101 also demonstrated a dose-
dependent antibody response to the VEE virus vector. This re-
sponse was consistent with results in preclinical studies, and it is
possible that the anti-vector responses played a role in the limited
anti-Gag immune response. However, anti-VRP antibody re-
sponses do not appear to inhibit the ability of repeated injections
of VRP vaccines to boost immune responses to other antigens in
humans. In a clinical trial with a CMV VRP vaccine, anti-vector
antibodies developed in most subjects after a first dose and all
subjects after a second dose, but CMV gB-specific antibody titers
were boosted after the second and third doses of vaccine (5). Sim-
ilarly, in a cancer immunotherapy clinical trial comparing two
dose levels of a carcinoembryonic antigen (CEA) VRP vaccine,
after a single dose of vaccine the anti-vector antibody titer in-
creased dramatically and remained elevated throughout the pe-
riod of repeated immunizations. Despite this, there was a signifi-
cant increase in immune response for at least one postvaccination
time point versus prevaccination for all three assays (anti-CEA
antibody, IFN- ELISpot, and ICS) in the high-dose cohort (13).
The HVTN 040 and 059 trials also demonstrated the difficulty
inherent in process development for biological products such as
virus-vectored vaccines. Given the fact that the vast majority of
FIG 6 ICS 2 weeks after 3rd vaccination (day 98). Data were obtained only for U.S. participants in study HVTN 059. A solid dot represents a positive response,
and an open dot represents a negative response. Numbers at the top show the number of responders/number of assay results and the percentage with a positive
result. For each box plot, 25% of the data points lie below the box and 25% lie above the box, and the horizontal line inside the box is the median. The vertical
lines (whiskers) above and below the box extend to the most extreme data point, which is no more than 1.5 times the height of the box.
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products that enter clinical trials do not successfully complete
phase III testing and become licensed, it is not feasible to complete
all process development activities, such as manufacturing scale-up
and long-term stability testing, before initiating clinical trials.
With the AVX101 vaccine, a single dose-response clinical trial
(HVTN 040) was originally planned. Because of issues with stabil-
ity, the HVTN 040 trial was halted after enrolling only the first two
dose level groups. After the first study was started, improvements
in scale-up of the manufacturing process provided an opportunity
to test a higher dose level in the second study (HVTN 059). How-
ever, because of issues with documentation at the contract re-
search organization (CRO) where the vaccine was manufactured,
the second trial was also halted prior to completion of dosing
participants in Southern Africa. Stability issues, including loss of
potency and critical storage conditions, may come to light only
once trials are under way, as was the case for HVTN 040. Further,
many candidate HIV-1 prophylactic vaccines have their start in
small academic or biotech environments. For many, a contract
manufacturer is the only option for production of clinical-grade
material. Although these manufacturers may have passed audits
and have documented procedures in place, the developer of the
vaccine does not have complete control over the facility and pro-
cesses. As such, problems may arise at any point, including once a
trial is under way, that can result in halting a study.
Results in animals often are not completely predictive of results
in humans, but there is no alternative that is more predictive.
There are no in vitro models of immunogenicity that have dem-
onstrated good predictive ability. These hurdles, as well as the
challenges inherent in the manufacture of these complicated vac-
cines, face all vaccine developers. Despite these problems, and the
premature stopping of both trials, these studies were able to
address the primary and secondary objectives, to evaluate the
safety and tolerability and immunogenicity of increasing doses
of AVX101 given by s.c. injection. AVX101 was well tolerated,
but the cellular and humoral immune responses were disap-
pointingly modest compared with the promising preclinical
results.
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